Clinical Trial Update: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) [Phase 3]

View source ↗

Summary

An open-label extension study of depemokimab (GSK3511294) in asthma patients who previously enrolled in earlier trials; the Phase 3 extension is completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Depemokimab (depemokimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2026-01-15